Premium
A human B‐cell lymphoma line with a de novo multidrug resistance phenotype
Author(s) -
Mohammad Ramzi M.,
Mohamed Anwar N.,
Kukuruga Mark,
Smith Mitchell R.,
AlKatib Ayad
Publication year - 1992
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19920315)69:6<1468::aid-cncr2820690626>3.0.co;2-8
Subject(s) - lymphoma , cell culture , flow cytometry , antigen , monoclonal antibody , biology , immunophenotyping , microbiology and biotechnology , cancer research , medicine , antibody , immunology , pathology , genetics
A human diffuse large cell lymphoma line (WSU‐DLCL) expressing multidrug resistance (MDR) was established from a patient with primary chemotherapy‐resistant disease. This cell line has the same phenotypic features as malignant cells from the patient. The established cell line has features of a mature B‐cell neoplasm with no evidence for commitment to other lineages. WSU‐DLCL grows in suspension forming relatively large clumps of cells with a doubling time of 20 hours. By light microscopic examination, the cells are very large with primitive lymphoid features, have a large amount of cytoplasm containing numerous vacuoles and an irregular outline. Immunophenotypic characterization by monoclonal antibodies and flow cytometric analysis showed a monoclonal IgM kappa B‐cell phenotype with high expression of the multidrug‐resistant P‐glycoprotein compared with either normal peripheral blood lymphocytes or cells of the REH cell line. The cells were negative for T‐cell and myeloid/monocyte antigens as well as Epstein‐Barr virus nuclear antigen (EBNA). In addition, the cell line expressed high levels of MDR RNA. DNA histogram generated by flow cytometry indicated a DNA index of 1.83. Cytogenetic analysis confirmed hypertriploidy and showed complex chromosomal abnormalities including 14q+. This cell line should be a valuable tool to study the role of the MDR gene in the primary resistance of lymphomas to chemotherapy and to facilitate therapeutic investigations. Cancer 1992; 69:1468‐1474.